Match!
Stephen H. Caldwell
University of Virginia
348Publications
52H-index
12.9kCitations
Publications 349
Newest
#1William Bernal (University of Cambridge)H-Index: 38
#2Stephen H. Caldwell (UVA: University of Virginia)H-Index: 52
Last.Ton Lisman (UMCG: University Medical Center Groningen)H-Index: 51
view all 3 authors...
Source
Source
#1Kathy M. Nilles (NU: Northwestern University)H-Index: 2
#2Stephen H. Caldwell (UVA: University of Virginia)H-Index: 52
Last.Steven L. Flamm (NU: Northwestern University)H-Index: 36
view all 3 authors...
Source
#1Jonathan G. Stine (PSU: Pennsylvania State University)H-Index: 2
#2Nicolas M. Intagliata (UVA: University of Virginia)H-Index: 11
Last.Curtis K. Argo (UVA: University of Virginia)H-Index: 27
view all 7 authors...
Introduction and Aim Hemostatic disorders in chronic liver disease and cirrhosis show continued expansion of research efforts. However, clinical decision making is often practiced on an individual patient level as consensus guidelines are lacking. We aimed to better assess individual day-to-day clinical practice through gauging clinicians’ responses to common clinical scenarios.
Source
#1Andrew Wang (UVA: University of Virginia)H-Index: 41
#2Elliot Smith (UVA: University of Virginia)H-Index: 2
Last.Stephen H. Caldwell (UVA: University of Virginia)H-Index: 52
view all 6 authors...
Source
#1Nicolas M. Intagliata (UVA: University of Virginia)H-Index: 11
#2Jessica P.E. Davis (UVA: University of Virginia)H-Index: 2
Last.Stephen H. Caldwell (UVA: University of Virginia)H-Index: 52
view all 7 authors...
Abstract Background/aims The coagulation system is known to be rebalanced but fragile in stable cirrhosis. Acute kidney injury (AKI) is common in these patients and associated with an increased bleeding risk. We aimed to assess coagulation parameters in this population. Methods We prospectively enrolled 43 hospitalized patients with decompensated cirrhosis with (n = 22) or without (n = 21) AKI. Coagulation factor levels, viscoelastic coagulation assay, and thrombin generation assay were performe...
Source
#1Michael Trauner (Medical University of Vienna)H-Index: 76
#2Aliya Gulamhusein (U of T: University of Toronto)H-Index: 7
Last.Kris V. KowdleyH-Index: 76
view all 20 authors...
5 CitationsSource
#2Charles S. Greenberg (MUSC: Medical University of South Carolina)H-Index: 8
Last.Stephen H. Caldwell (UVA: University of Virginia)H-Index: 52
view all 4 authors...
Description This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership. The intent is to evaluate the current data on mechanism of altered coagulation in patients with cirrhosis, provide guidance on the use of currently available testing of the coagulation cascade, and help practitioners use anticoagulation and pro-coagulants appropria...
2 CitationsSource
#1Blake A. Niccum (Harvard University)H-Index: 3
#2Jonathan G. Stine (Penn State Milton S. Hershey Medical Center)H-Index: 2
Last.Neeral L. Shah (University of Virginia Health System)H-Index: 17
view all 6 authors...
IN BRIEF Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV...
Source
#1Arun J. Sanyal (VCU: Virginia Commonwealth University)H-Index: 102
#2Stephen A. Harrison (Pinnacle Financial Partners)H-Index: 26
Last.Zachary Goodman (Inova Fairfax Hospital)H-Index: 76
view all 19 authors...
1 CitationsSource
12345678910